Cargando…

Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019

OBJECTIVE: To compare the burden of multiple sclerosis disease indicators in the Asia-Pacific countries, China and globally through the Global Burden of Disease 2019 (GBD2019) Database, and to analyse the changes of multiple sclerosis disease burden in China from 1990 to 2019. STUDY DESIGN: Observat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Min, Zhou, Na, Duan, Shengnan, Zhong, Hua, Jiang, Rong, Yuan, Ni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743400/
https://www.ncbi.nlm.nih.gov/pubmed/36600393
http://dx.doi.org/10.1136/bmjopen-2022-066335
_version_ 1784848718784102400
author Li, Min
Zhou, Na
Duan, Shengnan
Zhong, Hua
Jiang, Rong
Yuan, Ni
author_facet Li, Min
Zhou, Na
Duan, Shengnan
Zhong, Hua
Jiang, Rong
Yuan, Ni
author_sort Li, Min
collection PubMed
description OBJECTIVE: To compare the burden of multiple sclerosis disease indicators in the Asia-Pacific countries, China and globally through the Global Burden of Disease 2019 (GBD2019) Database, and to analyse the changes of multiple sclerosis disease burden in China from 1990 to 2019. STUDY DESIGN: Observational study based on the Global Burden of Disease. SETTING: The relevant incidence, prevalence, death and disability-adjusted life year (DALY) rates and corresponding age-standardised rates (ASRs) and sociodemographic index (SDI) in China, globally and in Asia-Pacific countries were extracted from the GBD2019 Database to further study the age-standardised incidence, prevalence and mortality, and the relationship between DALY rate and SDI. RESULTS: Various disease burden indicators of multiple sclerosis in China are at low level in the world, and the prevalence, incidence and DALY rates have slowly increased from 1990 to 2019. During this period, the age-standardised prevalence rate (ASPR) of multiple sclerosis in China showed an upward trend, while the age-standardised death rate (ASDR), age-standardised DALY rate (ASR-DALY) and age-standardised incidence rate all decreased to varying degrees, which were roughly consistent with the global amplitude changes, and all indicators are similar to most countries in the Asia-Pacific region. As the value of the SDI increases, the ASPR of multiple sclerosis was trending upward, and the ASDR was trending downward. CONCLUSION: Compared with other countries in the Asia-Pacific region, China is in a low state of disease burden indicators. However, as a developing country and the most populous country in the world, the total number of patients is not small, and as a rare disease, the treatment cost is relatively expensive, and the treatment cost of the complications caused by the disease is not low. The construction of the medical security system should be strengthened to reduce its burden on individuals, families and society.
format Online
Article
Text
id pubmed-9743400
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-97434002022-12-13 Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019 Li, Min Zhou, Na Duan, Shengnan Zhong, Hua Jiang, Rong Yuan, Ni BMJ Open Health Economics OBJECTIVE: To compare the burden of multiple sclerosis disease indicators in the Asia-Pacific countries, China and globally through the Global Burden of Disease 2019 (GBD2019) Database, and to analyse the changes of multiple sclerosis disease burden in China from 1990 to 2019. STUDY DESIGN: Observational study based on the Global Burden of Disease. SETTING: The relevant incidence, prevalence, death and disability-adjusted life year (DALY) rates and corresponding age-standardised rates (ASRs) and sociodemographic index (SDI) in China, globally and in Asia-Pacific countries were extracted from the GBD2019 Database to further study the age-standardised incidence, prevalence and mortality, and the relationship between DALY rate and SDI. RESULTS: Various disease burden indicators of multiple sclerosis in China are at low level in the world, and the prevalence, incidence and DALY rates have slowly increased from 1990 to 2019. During this period, the age-standardised prevalence rate (ASPR) of multiple sclerosis in China showed an upward trend, while the age-standardised death rate (ASDR), age-standardised DALY rate (ASR-DALY) and age-standardised incidence rate all decreased to varying degrees, which were roughly consistent with the global amplitude changes, and all indicators are similar to most countries in the Asia-Pacific region. As the value of the SDI increases, the ASPR of multiple sclerosis was trending upward, and the ASDR was trending downward. CONCLUSION: Compared with other countries in the Asia-Pacific region, China is in a low state of disease burden indicators. However, as a developing country and the most populous country in the world, the total number of patients is not small, and as a rare disease, the treatment cost is relatively expensive, and the treatment cost of the complications caused by the disease is not low. The construction of the medical security system should be strengthened to reduce its burden on individuals, families and society. BMJ Publishing Group 2022-12-08 /pmc/articles/PMC9743400/ /pubmed/36600393 http://dx.doi.org/10.1136/bmjopen-2022-066335 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Economics
Li, Min
Zhou, Na
Duan, Shengnan
Zhong, Hua
Jiang, Rong
Yuan, Ni
Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_full Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_fullStr Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_full_unstemmed Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_short Burden and trends of multiple sclerosis in China from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
title_sort burden and trends of multiple sclerosis in china from 1990 to 2019: a systematic analysis for the global burden of disease study 2019
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743400/
https://www.ncbi.nlm.nih.gov/pubmed/36600393
http://dx.doi.org/10.1136/bmjopen-2022-066335
work_keys_str_mv AT limin burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT zhouna burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT duanshengnan burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT zhonghua burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT jiangrong burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019
AT yuanni burdenandtrendsofmultiplesclerosisinchinafrom1990to2019asystematicanalysisfortheglobalburdenofdiseasestudy2019